You are here: Industry Insights > cusatuzumab

News List

Janssen Affiliate Cilag GmbH International Discontinues Collaboration and License Agreement with argenx for Cusatuzumab americanpharmaceuticalreview
June 09, 2021
Cilag GmbH International, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced its decision to discontinue the collaboration and license agreement with argenx for cusatuzumab, an investigational therapeutic antibody that targets ...
Johnson & Johnson pays $300m to develop cusatuzumab pharmatimes
December 06, 2018
Johnson & Johnson's Janssen has entered into an agreement potentially worth up to $1.6 billion to develop and market Argenx' cusatuzumab for a number of cancers, including haematological malignancies.
Johnson & Johnson pays $300 million upfront under deal to develop argenx's cancer drug cusatuzumab firstwordpharma
December 03, 2018
Johnson & Johnson's Janssen Pharmaceutical unit entered an agreement potentially worth up to $1.6 billion to develop and market argenx's cusatuzumab in a number of cancers, including haematological malignancies, the companies announced Monday.
Johnson & Johnson pays $300 million upfront under deal to develop argenx's cancer drug cusatuzumab firstwordpharma
December 03, 2018
Johnson & Johnson's Janssen Pharmaceutical unit entered an agreement potentially worth up to $1.6 billion to develop and market argenx's cusatuzumab in a number of cancers, including haematological malignancies, the companies announced Monday.